Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Hang Lee, Ph.D.


This page shows the publications co-authored by Hang Lee and Joy Tsai.
Connection Strength

  1. Effects of Combination Denosumab and High-Dose Teriparatide Administration on Bone Microarchitecture and Estimated Strength: The DATA-HD HR-pQCT Study. J Bone Miner Res. 2021 01; 36(1):41-51.
    View in: PubMed
    Score: 0.217
  2. Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial. Lancet Diabetes Endocrinol. 2019 10; 7(10):767-775.
    View in: PubMed
    Score: 0.202
  3. Effects of Teriparatide, Denosumab, or Both on Spine Trabecular Microarchitecture in DATA-Switch: a Randomized Controlled Trial. J Clin Densitom. 2017 Oct - Dec; 20(4):507-512.
    View in: PubMed
    Score: 0.173
  4. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up). Bone. 2017 May; 98:54-58.
    View in: PubMed
    Score: 0.170
  5. Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study. Bone. 2017 02; 95:20-25.
    View in: PubMed
    Score: 0.166
  6. Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate. J Clin Endocrinol Metab. 2015 Jul; 100(7):2718-23.
    View in: PubMed
    Score: 0.150
  7. Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study. J Bone Miner Res. 2015 Jan; 30(1):39-45.
    View in: PubMed
    Score: 0.146
  8. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013 Jul 06; 382(9886):50-6.
    View in: PubMed
    Score: 0.131
  9. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015 Sep 19; 386(9999):1147-55.
    View in: PubMed
    Score: 0.038
  10. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014 May; 99(5):1694-700.
    View in: PubMed
    Score: 0.034
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.